Jim Birchenough
Stock Analyst at Wells Fargo
(2.83)
# 1,657
Out of 5,112 analysts
30
Total ratings
52.63%
Success rate
37.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.44 | +353.51% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $55.97 | +25.07% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $25.85 | +85.69% | 3 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.09 | +11,826.61% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $3.87 | +261.76% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $29.89 | +385.11% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $118.78 | -46.96% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $71.97 | - | 1 | Jul 7, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $21.89 | +155.82% | 3 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | $734 | $746.36 | -1.66% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $6.30 | +2,757.14% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $8.51 | +287.78% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.44
Upside: +353.51%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $55.97
Upside: +25.07%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $25.85
Upside: +85.69%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.09
Upside: +11,826.61%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $3.87
Upside: +261.76%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $29.89
Upside: +385.11%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $118.78
Upside: -46.96%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $71.97
Upside: -
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $21.89
Upside: +155.82%
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $746.36
Upside: -1.66%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $6.30
Upside: +2,757.14%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $8.51
Upside: +287.78%